Friendswood, Texas, U.S., September 24, 2026
Castle Biosciences, Inc. has announced findings from a new study highlighting the potential clinical value of molecular guidance when selecting systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). The study evaluated the company’s AdvanceAD-Tx™ test, a molecular diagnostic designed to provide information that may help physicians identify treatment options associated with a patient’s individual disease biology. Published findings suggest that patients with atopic dermatitis can show different molecular profiles and treatment responses, supporting the potential value of a more personalized approach to therapeutic selection. Atopic dermatitis is a chronic inflammatory skin disease that can substantially affect patients’ quality of life, and treatment selection may require consideration of disease severity, previous therapies, comorbidities and expected response. Castle Biosciences said the findings reinforce the potential role of AdvanceAD-Tx in supporting treatment decisions for patients who require systemic therapy.
Study Examines Treatment Response in Atopic Dermatitis
The study investigated the relationship between molecular profiles and clinical responses to systemic therapies in patients with atopic dermatitis. According to Castle Biosciences, the research provides evidence that molecular characteristics of AD lesions may contain information relevant to treatment response. The findings are important because systemic treatments used for moderate-to-severe atopic dermatitis can produce different levels of response among individual patients. Physicians currently use clinical characteristics and treatment history to guide therapeutic selection, but these factors may not fully capture the underlying biological differences between patients. Molecular testing could potentially add another layer of information by characterizing disease-associated biological pathways and helping clinicians make more individualized treatment decisions.
AdvanceAD-Tx Supports Precision Treatment Selection
AdvanceAD-Tx is a molecular diagnostic test developed by Castle Biosciences to provide information about the biological characteristics of atopic dermatitis. The company says the test analyzes molecular signals associated with disease biology and can generate a report intended to help clinicians evaluate treatment options. The approach reflects the broader movement toward precision medicine in dermatology, where molecular information can complement conventional clinical assessment. Rather than relying exclusively on disease severity or previous treatment history, molecular testing seeks to identify biological characteristics that could influence therapeutic response. Castle Biosciences is developing AdvanceAD-Tx as a tool intended to support conversations between physicians and patients when considering systemic treatment options.
Advertisement
Molecular Data Could Address Treatment Selection Challenges
Selecting an effective systemic treatment for moderate-to-severe atopic dermatitis can be challenging because individual patients may respond differently to available therapies. Some patients may achieve substantial disease control, while others may experience incomplete responses or require changes in treatment because of tolerability, loss of efficacy or other clinical considerations. The new study adds to evidence supporting the investigation of molecular biomarkers as a way to better understand these differences. According to Castle Biosciences, the study’s findings demonstrate a need for molecular information that can complement traditional clinical decision-making. The company believes this type of information could potentially help physicians identify therapies more closely aligned with a patient’s underlying disease biology. Atopic dermatitis affects a large patient population worldwide and is characterized by chronic inflammation, itching and recurring skin lesions. Although multiple systemic therapies are now available for patients with moderate-to-severe disease, treatment response remains variable. The development of molecular diagnostics such as AdvanceAD-Tx reflects efforts to move beyond a one-size-fits-all treatment approach and toward more individualized care. By analyzing biological signals within diseased tissue, molecular tests may provide information that is not readily available through routine clinical assessment alone. However, the clinical utility of any diagnostic test depends on evidence demonstrating that test-guided decisions can meaningfully improve treatment selection and patient outcomes.
Castle Biosciences’ latest study therefore adds to the company’s ongoing development of molecular guidance for atopic dermatitis treatment selection. The findings support continued evaluation of AdvanceAD-Tx as a potential tool for integrating molecular information into dermatology practice. Further research will be important to establish how the test performs across broader patient populations and clinical settings and whether its use can lead to improved treatment outcomes. The work highlights the expanding role of molecular diagnostics and precision medicine in inflammatory skin disease and the potential for biological information to complement conventional approaches to therapeutic decision-making.
Source: Castle Biosciences press release
